Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + fluzoparib as first-line maintenance for stage IV NSCLC (Phase II)
ChiCTR2200059716Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and fluzoparib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: progression-free survival. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
camrelizumabfluzoparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200059716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059716.